Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis

By Confavreux C.   Chapurlat R.  

Osteoporosis International, Vol. 22, Iss. 4, 2011-04 ,pp. : 1023-1036

Springer Publishing Company

Access to resources Recommend Favorite

Rosuvastatin‐Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1718-1728

John Wiley & Sons Inc

Access to resources Recommend Favorite

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis

By Haberhauer Guenther  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 9-10, 2010-05 ,pp. : 220-224

Springer Publishing Company

Access to resources Recommend Favorite

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

By Bonafede Machaon   Joseph George J.   Princic Nicole   Harrison David J.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1120-1128

Informa Healthcare

Access to resources Recommend Favorite

A narrative literature review of the impact of anti-TNFα treatment on the occupational performance of people with rheumatoid arthritis or ankylosing spondylitis

By McArthur Margaret   Birt Linda   Goodacre Lynne  

The British Journal of Occupational Therapy, Vol. 76, Iss. 10, 2013-10 ,pp. : 456-469

College of Occupational Therapists

Access to resources Recommend Favorite